Epilepsy Therapy Project invests in ICVrx; Particle Sciences, Celanese to team on drug eluting devices;

> Epilepsy Therapy Project, a nonprofit group whose mission is to help accelerate new therapies for people living with epilepsy, has invested an undisclosed amount in ICVrx, a company developing therapies for central nervous system disorders. The investment will help ICVrx develop a pump to deliver anti-epilepsy drugs. Release

> Drug delivery company CIMA Labs in Brooklyn Park, MN, will now be run by Israeli firm Teva Pharmaceutical Industries as part of Teva's acquisition of CIMA parent company Cephalon. Cephalon had acquired CIMA Labs in 2004. Story

> Particle Sciences and Celanese EVA Performance Polymers are getting together to streamline development of drug eluting devices. Particle Sciences release

> The problem of multidrug resistance can possibly be solved through the use of multifunctional nanocarriers for drug delivery. Abstract

> LyoGo, a company that specializes in developing devices to deliver injected freeze-dried drugs, diagnostics and vaccines has become a tenant in the Purdue Research Park. LyoGo release

Suggested Articles

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.

Delivery specialist IntelGenx struck two deals to develop oral films for prescription psychedelics this summer with Canada's Cybin and ATAI.